What is the address of MEDISOINS BRUXELLES?

The registered office of MEDISOINS BRUXELLES is located at Geurstraat 9, 1070 Anderlecht.

Is MEDISOINS BRUXELLES still active?

Yes. According to the CBE (29 September 2026) MEDISOINS BRUXELLES is active, legal situation “Normale toestand”, started on 30 December 2008.

Is MEDISOINS BRUXELLES registered on Peppol?

No, MEDISOINS BRUXELLES is currently not registered on the Peppol network.

What is the enterprise number of MEDISOINS BRUXELLES?

The enterprise number of MEDISOINS BRUXELLES is BE0809009197.

When was MEDISOINS BRUXELLES founded?

MEDISOINS BRUXELLES was founded on 30 December 2008.

Who are the directors of MEDISOINS BRUXELLES?

According to the 2025 annual accounts, the directors of MEDISOINS BRUXELLES are: Igor Faidherbes.

Is MEDISOINS BRUXELLES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 December 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did MEDISOINS BRUXELLES make in 2025?

MEDISOINS BRUXELLES posted a profit after taxes of € 21,732 in financial year 2025.

What is the revenue of MEDISOINS BRUXELLES?

As a small company, MEDISOINS BRUXELLES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 65,201.

MEDISOINS BRUXELLES (Private Limited) - Anderlecht

Dossier MEDISOINS BRUXELLES, printed on 29 September 2026 from databakkes.be/en/0809009197/medisoins-bruxelles. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

MEDISOINS BRUXELLES from Anderlecht, company number BE0809009197, closed financial year 2025 with a result of € 21,732 after tax. For that financial year MEDISOINS BRUXELLES recorded a gross margin of € 65,201 and equity of € 177,415. Compared with financial year 2024, the result moved from € -2,957 to € 21,732. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.

What it is worth Healthy

€ 177,415

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 21,732

▲ still € 2,957 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 111,844

▲ 76% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 35,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 40,801

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 18,204

▼ 41% vs 2024

€ 14,792 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 24,698

▲ 25% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 18,609

▲ € 18,559 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 35,090 Gross margin 2022: € 35,090 First fiscal year in the series	€ 25,616 Gross margin 2023: € 25,616 ▼ 27% vs 2022 (€ 35,090) Unfavourable step	€ 25,775 Gross margin 2024: € 25,775 ▲ 1% vs 2023 (€ 25,616) Favourable step	€ 65,201 Gross margin 2025: € 65,201 ▲ 153% vs 2024 (€ 25,775) Favourable step	▲ 153%
Profit after taxes	€ 7,088 Profit after taxes 2022: € 7,088 First fiscal year in the series	€ -14,600 Profit after taxes 2023: € -14,600 ▼ € 21,688 vs 2022 (€ 7,088) Unfavourable step	€ -2,957 Profit after taxes 2024: € -2,957 ▲ € 11,643 vs 2023 (€ -14,600) Favourable step	€ 21,732 Profit after taxes 2025: € 21,732 ▲ € 24,688 vs 2024 (€ -2,957) Favourable step	▲ € 24,688
Equity	€ 208,233 Equity 2022: € 208,233 First fiscal year in the series	€ 193,640 Equity 2023: € 193,640 ▼ 7% vs 2022 (€ 208,233) Unfavourable step	€ 190,683 Equity 2024: € 190,683 ▼ 2% vs 2023 (€ 193,640) Unfavourable step	€ 177,415 Equity 2025: € 177,415 ▼ 7% vs 2024 (€ 190,683) Unfavourable step	▼ 7%
Total debts	€ 30,536 Total debts 2022: € 30,536 First fiscal year in the series	€ 58,838 Total debts 2023: € 58,838 ▲ 93% vs 2022 (€ 30,536) Unfavourable step	€ 50,712 Total debts 2024: € 50,712 ▼ 14% vs 2023 (€ 58,838) Favourable step	€ 86,011 Total debts 2025: € 86,011 ▲ 70% vs 2024 (€ 50,712) Unfavourable step	▲ 70%
Cash	€ 103,424 Cash 2022: € 103,424 First fiscal year in the series	€ 65,295 Cash 2023: € 65,295 ▼ 37% vs 2022 (€ 103,424) Unfavourable step	€ 63,533 Cash 2024: € 63,533 ▼ 3% vs 2023 (€ 65,295) Unfavourable step	€ 111,844 Cash 2025: € 111,844 ▲ 76% vs 2024 (€ 63,533) Favourable step	▲ 76%
Retained profit	€ 189,633 Retained profit 2022: € 189,633 First fiscal year in the series	€ 175,040 Retained profit 2023: € 175,040 ▼ 8% vs 2022 (€ 189,633) Unfavourable step	€ 172,083 Retained profit 2024: € 172,083 ▼ 2% vs 2023 (€ 175,040) Unfavourable step	€ 158,815 Retained profit 2025: € 158,815 ▼ 8% vs 2024 (€ 172,083) Unfavourable step	▼ 8%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 35,000 Dividend 2025: € 35,000 Unchanged (€ 0) Unchanged
Bank debt	€ 19,759 Bank debt 2022: € 19,759 First fiscal year in the series	€ 49,647 Bank debt 2023: € 49,647 ▲ 151% vs 2022 (€ 19,759) Unfavourable step	€ 30,841 Bank debt 2024: € 30,841 ▼ 38% vs 2023 (€ 49,647) Favourable step	€ 18,204 Bank debt 2025: € 18,204 ▼ 41% vs 2024 (€ 30,841) Favourable step	▼ 41%
Balance sheet total	€ 238,769 Balance sheet total 2022: € 238,769 First fiscal year in the series	€ 252,478 Balance sheet total 2023: € 252,478 ▲ 6% vs 2022 (€ 238,769) Unchanged	€ 241,395 Balance sheet total 2024: € 241,395 ▼ 4% vs 2023 (€ 252,478) Unchanged	€ 263,426 Balance sheet total 2025: € 263,426 ▲ 9% vs 2024 (€ 241,395) Unchanged	▲ 9%

Key figures of MEDISOINS BRUXELLES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDISOINS BRUXELLES?

What happened at MEDISOINS BRUXELLES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 26, 2026 New annual accounts for financial year 2025: profit of € 21,732. Source: NBB ↗
Mar 2, 2009 New establishment in Anderlecht. KBO
Dec 30, 2008 Start of the company according to the CBE. KBO

In short

From € 7,088 profit in 2022 to € 21,732 profit in 2025.

Paid € 37,651 in corporate taxes since 2022.

Best year ever: 2025, with € 21,732 profit.

Paid out € 35,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at MEDISOINS BRUXELLES? We notify you, reason included.

Follow MEDISOINS BRUXELLES

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Igor Faidherbes

MEDISOINS BRUXELLES

Behind MEDISOINS BRUXELLES is Igor Faidherbes.

See the full network in the app

Directors

According to the 2025 annual accounts

Igor Faidherbes

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Geurstraat 9

1070 Anderlecht

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0809.009.197
VAT number: BE 0809.009.197
Registered office: Geurstraat 9, 1070 Anderlecht
Names & denominations: MEDISOINS BRUXELLES
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 30 December 2008
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗